Zai Lab gets FDA fast track status for lung cancer treatment
Source: SeekingAlpha
2025-05-19 09:09:28 ET
More on Zai Lab
- Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript
- Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth
- Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks
- Zai Lab Q1 2025 Earnings Preview
- Zai Lab gets China's acceptance for label expansion of repotrectinib
Read the full article on Seeking Alpha
For further details see:
Zai Lab gets FDA fast track status for lung cancer treatment
Zai Lab Limited
NASDAQ: ZLAB
ZLAB Trading
-1.63% G/L:
$18.365 Last:
202,921 Volume:
$18.85 Open:
ZLAB Latest News
February 26, 2026 07:00:00 am
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
ZLAB Stock Data
$2,174,273,322
105,108,310
0.9%
39
N/A
Biotechnology & Life Sciences
Healthcare
CN
Shanghai
